Spironolactone
Product Images NDC 53808-0979

4 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 53808-0979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 25mg (Spironolactone 25mg)

Label Image For 25mg (Spironolactone 25mg)
Label for Spironolactone 25 mg tablets from State of Florida DOH Central Pharmacy. The label includes a lot number and packaging date, with text indicating prescription-only status. The label also shows a barcode and the location of the pharmacy in Tallahassee, FL.*
FDA Label Image

25aa223c-figure-01 (Spironolactone Tablets Usp 1)

25aa223c-figure-01 (Spironolactone Tablets Usp 1)
Chemical structure of spironolactone, showing a steroid backbone with a lactone ring and thioacetate functional groups, consistent with its molecular configuration.*
FDA Label Image

25aa223c-figure-02 (Spironolactone Tablets Usp 2)

25aa223c-figure-02 (Spironolactone Tablets Usp 2)
This is a Kaplan-Meier survival curve graph comparing Spironolactone and Placebo groups over time in months. The Y-axis represents probability, while the X-axis shows months, illustrating the probability trend for Spironolactone (n=822) and Placebo (n=841) groups with a noted log-rank p-value < 0.001.*
FDA Label Image

25aa223c-figure-03 (Spironolactone Tablets Usp 3)

25aa223c-figure-03 (Spironolactone Tablets Usp 3)
A forest plot showing hazard ratios (HR) and 95% confidence intervals (CI) for Spironolactone versus placebo across various subgroups including age, sex, race, LVEF, heart failure type, NYHA class, diabetes presence, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot visually compares treatment effects with individual subgroup HRs and confidence intervals marked.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.